Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer

NCT00902291 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00902291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00902291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
April 30, 2012
Enrollment
205 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, pancreatic ductal, pancreatic cancer, pancreatic disease